<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2812211519
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SELEKTINE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MELOXICAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HAYAT PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HAYAT PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HAYAT PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AC06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Selektine contains the active substance meloxicam. Meloxicam belongs to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAIDs) which are used to reduce inflammation and pain in joints and muscles. Selektine is used for the short-term treatment of flare-ups of osteoarthritis, and for the long-term treatment of: (rheumatoid arthritis, ankylosing spondylitis (also known as Bechterew&rsquo;s Disease)).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Selektine tablets</strong><br />If you are allergic to meloxicam, aspirin or other anti-inflammatory medicines (NSAIDs), or any of the other ingredients of Selektine tablets, listed in section 6 below, or during the last three months of pregnancy, or children and adolescents under 16 years of age. If you have suffer from any of the following signs after taking aspirin or other NSAIDs: wheezing, chest tightness, breathlessness, skin rashes/nettle rash, sudden skin or&nbsp;mucosal swelling, such as swelling around the eyes, face, lips, mouth or throat, possibly making breathing difficult, after previous therapy with NSAIDs and history of bleeding in your stomach or intestines, holes in your<br />stomach or intestines, ulcers or bleeding in your stomach or intestines, recent or history of stomach or peptic ulcers or bleeding (ulceration or bleeding occurring at least twice), severely impaired liver function, non dialysed severe kidney failure, recent bleeding in the brain, any kind of bleeding disorders, severe heart failure, intolerance to some sugars as this product contains lactose.<br /><strong>Take special care with Selektine tablets</strong><br />Medicines such as Selektine may be associated with a small increased risk of heart attack or stroke. Any risk is more likely with high doses and prolonged treatment. Do not take more than the recommended dose. Do not take Selektine for longer than it is prescribed for you. If you have heart problems, previous stroke or think that you might be at risk of these conditions, you should discuss your treatment with your doctor or pharmacist. For example, if you: have high blood pressure, have high levels of sugar in the blood, have high levels of cholesterol in the blood, are a smoker. Stop your treatment with Selektine immediately as soon as you notice bleeding (causing tar coloured stools) or ulceration of your digestive tract (causing abdominal pain). Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of Selektine, appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis.<br />These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first weeks of treatment. If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of Selektine, you must not be re-started on Selektine at any time. If you develop a rash or these skin symptoms, stop taking Selektine, seek urgent advice from a doctor and tell him that you are taking this medicine. Selektine is not appropriate,&nbsp; if you require immediate relief from acute pain. Selektine may hide the symptoms of infection (e.g. fever). If you think you may have an infection you should see your doctor. As it will be necessary to adjust the treatment, it is important to ask your doctor&rsquo;s advice before you take Selektine in case of: a history of inflammation of the gullet, inflammation of the stomach or a history of any other disease of the digestive tract, high blood pressure, older age, heart, liver or kidney disease, high levels of sugar in the blood reduced blood volume which may occur if you have a serious blood loss or burn, surgery or low fluid intake, intolerance to some sugars diagnosed by your doctor as this product contains&nbsp;lactose, high potassium levels in the blood previously diagnosed by your doctor. Your doctor will need to<br />monitor your progress whilst on treatment.<br /><strong>Taking/using other medicines, herbal, or dietary supplements</strong><br />Please tell your doctor if you are taking any of the following medicines. These medicines may affect the way Selektine works. Also, Selektine may affect the way other medicines work: other NSAIDs, medicines which prevent blood clotting, medicines which break down blood clots, medicines to treat heart and kidney diseases, corticosteroids, cyclosporine, any diuretic medicine, your doctor may monitor your kidney function if you are taking diuretics, medicine to treat high blood pressure, lithium, selective serotonin reuptake inhibitors, methotrexate, cholestyramine levels, if you are a woman who uses an intrauterine contraceptive device (IUD), usually known as a coil.<br /><strong>Fertility, Pregnancy and breast-feeding</strong><br />Selektine may make it more difficult to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have problems to become pregnant. If a pregnancy is established during the use of Selektine, then the doctor is to be notified. During the first 6 months of pregnancy, your doctor may punctually prescribe you this medical product if necessary. During the last three months of pregnancy, do not use this product, because Selektine can have serious effects on your child, in particular cardiopulmonary and renal effects, even with only one administration. This product is not recommended during breastfeeding. Ask your doctor or pharmacist for advice before taking this medicine.<br /><strong>Driving and using machines</strong><br />Visual disturbances, including blurred vision, dizziness, drowsiness, vertigo or other central nervous system disturbances may occur with this product. If affected do not drive or operate machinery.<br /><strong>Important information about some of the ingredients of Selektine tablets</strong><br />This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Selektine tablet exactly as your doctor has told you. The recommended dose is:<br /><strong>Flare-ups of osteoarthritis:</strong> 7.5 mg once a day. This may be increased to 15 mg once a day.<br /><strong>Rheumatoid arthritis: </strong>15 mg once a day. This may be reduced to 7.5 mg once a day.<br /><strong>Ankylosing spondylitis: </strong>15 mg once a day. This may be reduced to 7.5 mg once a day. The tablets should be swallowed with water, or another drink, during a meal. The tablet can be divided into equal doses. <strong>Do not exceed the recommended maximum dose of 15 mg a day.</strong> If any of the statements listed under the heading &ldquo;Warnings and Precautions&rdquo; apply to you, your doctor may restrict your dose to 7.5 mg once a day. <strong>Selektine should not be given to children and adolescents under 16 years of age.</strong><br />If you feel that the effect of Selektine is too strong or too weak, or if after several days you do not feel any improvement in your condition, talk to your doctor or pharmacist.<br /><strong>If you take more Selektine tablets than you should&nbsp;</strong><br />Whether you have taken too many tablets or suspect an overdose, contact your doctor or go to your nearest hospital immediately. Symptoms following acute NSAID overdose are usually limited to: lack of energy, drowsiness, feeling sick and being sick, pain in the area of the stomach. These symptoms generally get better when you stop taking Selektine. You may suffer from bleeding of the stomach or intestines. <strong>Severe poisoning may result in serious drug reaction: </strong>high blood pressure, acute kidney failure, liver dysfunction, reduction/ flattening or standstill of breathing, loss of consciousness, seizures, the collapse of the blood circulation standstill of the heart, immediate allergic reactions, including fainting, shortness of breath, skin reactions.<br /><strong>If you forget to take Selektine tablets</strong><br />If you forget to take your dose on time, take it as soon as you remember unless it is nearly time for your next dose. Do not take a double dose to make up for a forgotten dose. Just take the next dose at the usual time.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine can cause side effects, although not everybody gets them. Stop taking Selektine and see a a doctor or go to a hospital immediately if you notice the following side effects:<br /><strong>Very common: affects more than 1 user in 10:</strong> Gastrointestinal adverse events such as indigestion, feeling sick and being sick, abdominal pain, constipation, flatulence, loose stools.<br /><strong>Common: affects 1 to 10 users in 100</strong>: Headache.<br /><strong>Uncommon: affects 1 to 10 users in 1,000:</strong> Dizziness, a feeling of dizziness or spinning, somnolence, anaemia, increase in blood pressure, flushing, sodium and water retention, increased potassium levels. This&nbsp; can lead to symptoms such as changes to your heartbeat, palpitations, muscle weakness, eructation, inflammation of the stomach, bleeding of the digestive tract, inflammation of the mouth, immediate allergic reactions, itching, skin rash, swelling caused by fluid retention including swollen ankles/legs, sudden skin or mucosal swelling, such as swelling around the eyes, face, lips, mouth or throat, possibly making breathing<br />difficult, momentary disturbance of liver function tests (e.g. raised liver enzymes like transaminases or an increase of the bile pigment bilirubin), your doctor can detect these using a blood test, disturbance of tests investigating kidney function (e.g. raised creatinine or urea)<br /><strong>Rare: affects 1 to 10 users in 10,000:</strong> Mood disorders, nightmares, abnormal blood count, including: (abnormal differential blood count, decreased number of white blood cells, decreased number of blood platelets). These side effects may lead to increased risk of infection and symptoms such as bruising or nosebleeds. Ringing in the ear, feeling your heartbeat, ulcers of the stomach or upper part of the small bowels, inflammation of the gullet, the onset of asthma attacks, severe blistering of the skin or peeling, nettle rash, visual disturbances including: (blurred vision, conjunctivitis), inflammation of the large bowel.<br /><strong>Very rare: affects less than 1 user in 10,000:</strong> Blistering reactions of the skin and erythema multiforme, erythema multiforme is a serious allergic skin reaction causing spots, red welts or purple or blistered areas, it can also affect the mouth, eyes and other moist body surfaces, inflammation of the liver, this can cause<br />symptoms such as: (yellowing of the skin or the eyeballs, the pain of the abdomen, loss of appetite), acute failure of the kidneys in particular in patients with risk factors such as heart disease, diabetes or kidney disease, a hole in the wall of the bowels.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.</li><li>Store below 30 ⁰C. Store in the original packaging.</li><li>Do not use Selektine tablets after the expiry date which is stated on the carton &amp; blister. The expiry date refers to the last day of that month.</li><li>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.&nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is meloxicam.</p><p>The other ingredients are Croscarmellose sodium, lactose, microcrystalline cellulose, silica, sodium laurilsulfate, magnesium stearate.<br />Each 7.5 mg tablet contains 7.65 mg meloxicam, and each 15 mg tablet contains 15.30 mg meloxicam.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Selektine 7.5 mg tablet is light yellow round biconvex engraved with “SL1” on one side and a break line on the other side and Selektine 15 mg tablet is light yellow flat circular with beveled edge engraved with “SL2” on one side and a break line on the other side and both are available in packs of 10 and 30 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Hayat Pharmaceutical Industries Co. PLC<br />P.O. Box 1564, Amman 11118 Jordan</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یحتوي سیلیكتین على المادة الفعالة میلوكسیكام. میلوكسیكام ینتمي إلى ممجموعة من الأدویة تسمى مضادات الالتھاب غیر الستیرویدیة و التي تستخدم لتخفیف الالتھاب والألم في المفاصل والعضلات. یستخدم سیلیكتین كعلاج قصیر الأمد لمرض ھشاشة العظام المشتعل وعلى المدى الطویل لعلاج(التھاب المفاصل الروماتویدي، التھاب الفقار اللاصق (المعروف أیضا باسم مرض بكتیریو)).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>قبل أن تتناول أقراص سیلیكتین<br />لاتتناول أقراص سیلیكتین</strong><br />إذا كان لدیك حساسیة من میلوكسیكام أو الأسبرین أو الأدویة المضادة للالتھابات الأخرى أو أي من المكونات الأخرى من أقراص سیلكتین، المدرجة في القسم 6 أدناه، أو إذا كنت في الأشھر الثلاثة الأخیرة من الحمل، أو الأطفال والمراھقین دون سن 16 عاما فى عمر. إذا كنت تعاني من أي من العلامات التالیة بعد تناول الأسبرین أو مضادات الالتھاب غیر الستیرویدیة الأخرى: الصفیر، ضیق الصدر، ضیق التنفس، الطفح الجلدي ، تورم الجلد أو الغشاء المخاطي المفاجئ ، مثل تورم حول العینین والوجھ والشفتین والفم أو الحلق ، مما قد یجعل التنفس صعبا، بعد العلاج السابق مع مضادات الالتھاب غیر الستیرویدیة وتاریخ من النزیف في المعدة أو الأمعاء، والثقوب في المعدة أو الأمعاء، والقرحة أو نزیف في معدتك أو الأمعاء، تاریخ مرضي أو إصابة حدیثة بقرحة المعدة الھضمیة أو النزیف (تقرح أو نزیف یحدث مرتین على الأقل)، وضعف شدید في وظائف الكبد، فشل كلوي حاد، ونزیف حدیث في الدماغ، أي نوع من اضطرابات النزیف، وفشل القلب الحاد، و عدم تحمل لبعض السكریات كما یحتوي ھذا المنتج اللاكتوز.<br /><strong>اتبع عنایة خاصة عند تناول أقراص سیلیكتین&nbsp;</strong></p><p>ترتبط الأدویة مثل سیلیكتین مع زیادة خطر الاصابة بأزمة قلبیة أو السكتة الدماغیة. أي خطر أكثر احتمالا مع جرعات عالیة والعلاج لفترات طویلة. لا تأخذ أكثر من الجرعة الموصى بھا. لا تأخذ سیلكتین لفترة أطول مما یوصف لك. إذا كان لدیك مشاكل في القلب، والسكتة الدماغیة السابقة أو تعتقد أنك قد تكون في خطر من ھذه الظروف، یجب علیك مناقشة العلاج الخاص بك مع الطبیب أو الصیدلي. على سبیل المثال إذا كنت تعاني من: ارتفاع ضغط الدم، وارتفاع مستویات السكر في الدم، وارتفاع مستویات الكولسترول في الدم، و إذا كنت مدخن. أوقف العلاج بسیلیكتین فورا بمجرد ملاحظة النزیف (مما تسبب في البراز بلون القطران) أو تقرح جھازك الھضمي (مما تسبب في آلام في البطن). وقد تم الإبلاغ عن احتمال الطفح الجلدي المھدد للحیاة (متلازمة ستیفنز جونسون، الانحلال البشرة السامة) عند استخدام سیلیكتین، و التي تظھر في البدایة على أنھا البقع المحمره المستھدفة أو بقع دائریة في كثیر من الأحیان مع بثور مركزیة على الجذع. علامات إضافیة للبحث عنھا تشمل القرحة في الفم، الحلق، الأنف، الأعضاء التناسلیة والتھاب الملتحمة. وغالبا ما یكون ھذا الطفح الجلدي المحتمل أن یھدد الحیاه مصحوباً بأعراض تشبھ الانفلونزا. الطفح الجلدي قد یتطور إلى تفتت واسع النطاق أو تقشیر الجلد. أعلى خطر حدوث ردود فعل الجلد خطیرة في غضون الأسابیع الأولى من العلاج. إذا كنت قد أصبت بمتلازمة ستیفنز جونسون أو سمیة البشرة الانحلال مع استخدام سیلیكتین، یجب أن لاتعود الى البدء باستخدام سیلیكتین في أي وقت. إذا أصبت بطفح جلدي أو أعراض الجلد ھذه، توقف عن تناول سیلیكتین، اطلب المشورة العاجلة من الطبیب وأخبره بأنك تتناول ھذا الدواء. سیلیكتین لیس مناسباً إذا كنت بحاجة إلى الإغاثة الفوریة من الألم الحاد. قد یخفي سیلیكتین أعراض العدوى (مثل الحمى). إذا كنت تعتقد أنھ قد تكون لدیك عدوى یجب أن ترى الطبیب. كما سیكون من الضروري ضبط العلاج، فمن المھم أن تأخذ نصیحة الطبیب قبل أن تتناول سیلیكتین في حالة: كان لدیك تاریخ مرضي من التھاب المريء، والتھاب المعدة أو أي مرض آخر من الجھاز الھضمي، وارتفاع ضغط الدم، و إذا كنت من كبار السن، و إذا كنت تعاني من مرض في القلب والكبد أو أمراض الكلى، وارتفاع مستویات السكر في الدم، وانخفاض حجم الدم التي قد تحدث إذا كان لدیك فقدان دم خطیرأو حرق، الجراحة أو قلة تناول السوائل، وعدم تحمل بعض السكریات التي تم تشخیصھا من قبل الطبیب الخاص بك حیث یحتوي ھذا المستحضر على اللاكتوز، وارتفاع مستویات البوتاسیوم في الدم و التي تم تشخیصھا من قبل الطبیب مسبقاً. سیحتاج طبیبك إلى مراقبة تقدمك أثناء العلاج.<br /><strong>تناول أدویة اخرى، أعشاب، أو مكملات غذائیة</strong><br />یرجی إخبار طبیبك إذا کنت تتناول أي من الأدویة التالیة. ھذه الأدویة قد تؤثر على طریقة عمل سیلكتین. أیضا، قد یؤثر سیلكتین على الطریقة التي تعمل بھا أدویة أخرى: مضادات الالتھاب غیر الستیرویدیة الأخرى والأدویة التي تمنع تخثر الدم والأدویة التي تحطم جلطات الدم والأدویة لعلاج أمراض القلب والكلى والكورتیكوستیرویدات والسیكلوسبورین وأي دواء مدر للبول، قد یقوم الطبیب بمراقبة وظائف الكلى إذا كنت تأخذ مدرات البول، و دواء لعلاج ارتفاع ضغط الدم، واللیثیوم، مثبطات إعادة امتصاص السیروتونین الانتقائیة، میثوتریكسات، ومستویات الكولسترامین، إذا كنت امرأة یستخدم جھاز منع الحمل داخل الرحم (اللولب)، وعادة ما تعرف باسم لفائف.<br /><strong>الحمل والإرضاع والإخصاب</strong><br />سیلیكتین قد تجعلك من الصعب أن تصبحي حاملا. یجب علیك إبلاغ الطبیب إذا كنتِ تخططین للحمل أو إذا كان لدیك مشاكل لتصبحي حاملا. إذا تم حدوث الحمل أثناء استخدام سیلیكتین،عندھا یتم إبلاغ الطبیب. خلال الأشھر الستة الأولى من الحمل قد یصف لك الطبیب ھذا المنتج الطبي إذا لزم الأمر. خلال الأشھر الثلاثة الأخیرة من الحمل، لا تستخدم ھذا المنتج، لأن سیلكتین یمكن أن یكون لھا آثار خطیرة على طفلك، ولا سیما القلب والأوعیة الدمویة والآثار الكلویة، حتى ولو جرعة واحدة فقط. لا ینصح ھذا المنتج أثناء الرضاعة الطبیعیة. اسأل طبیبك أو الصیدلي عن المشورة قبل تناول ھذا الدواء.<br /><strong>القیادة واستعمال الآلیات</strong><br />قد تحدث اضطرابات بصریة، بما في ذلك عدم وضوح الرؤیة، والدوخة، والنعاس، والدوار أو اضطرابات الجھاز العصبي المركزي الأخرى مع ھذا المنتج. إذا كان مصابا یجب عدم قیادة السیارة أو تشغیل الآلات.<br /><strong>معلومات مھمة عن بعض مكونات أقراص سیلیكتین</strong><br />یحتوي ھذا الدواء على اللاكتوز. إذا أخبرك طبیبك بأنك تعاني من عدم تحمل بعض السكریات، فاتصل بطبیبك قبل تناول ھذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>كیف تتناول أقراص سیلیكتین</strong><br />دائما تناول قرص سیلیكتین تماما كما قال لك طبیبك .الجرعة الموصى بھا ھي:<br /><strong>التھاب العمود الفقري</strong>&nbsp;: 7.5 مغ مرة واحدة في الیوم .ویمكن زیادة ھذا إلى 15 مغ مرة واحدة في الیوم.<br /><strong>التھاب المفاصل الروماتویدي</strong>: 15 مغ مرة واحدة في الیوم .ویمكن تخفیض ھذا إلى 7.5 مغ مرة واحدة في الیوم.<br />ا<strong>لتھاب الفقار اللاصق:&nbsp;</strong>15 مغ مرة واحدة في الیوم .ویمكن تخفیض ھذا إلى 7.5 مغ مرة واحدة في الیوم .یجب ابتلاع الأقراص مع الماء، أو شراب آخر، و أثناء وجبة الطعام .القرص یمكن تقسیمھ إلى جرعات متساویة .لا تتجاوز الجرعة القصوى الموصى بھا وھي 15 مغ یومیا. إذا كان أي من البیانات المدرجة تحت&nbsp; عنوان &quot;التحذیرات والاحتیاطات&quot; تنطبق علیك، قد یحدد طبیبك الجرعة إلى 7.5 مغ مرة واحدة في الیوم.<br /><strong>لا ینبغي أن یعطى سیلیكتین للأطفال والمراھقین الذین تقل أعمارھم عن 16 سنة.</strong></p><p>إذا شعرت أن تأثیر سیلیكتین قوي جدا أو ضعیف جدا، أو إذا لم تشعر بأي تحسن في حالتك بعد عدة أیام، تحدث مع طبیبك أو الصیدلي.<br /><strong>إذا تناولت أقراص سیلیكتین أكثر مما یجب</strong><br />سواء كنت قد تناولت الكثیر من الأقراص أو یشتبھ في جرعة زائدة، اتصل بطبیبك أو اذھب إلى أقرب مستشفى على الفور. الأعراضالتي تتبع جرعة زائدة حادة من مضادات الالتھاب الغیر ستیرویدیة تقتصر عادة على: نقص الطاقة، والنعاس، والشعور المرضى والمرضى، والألم في منطقة المعدة. ھذه الأعراض عموما الحصول على أفضل عند التوقف عن اتخاذ سیلكتین. قد تعاني من نزیف في المعدة أو الأمعاء. التسمم الشدید قد یؤدي إلى رد فعل خطیر للدواء: ارتفاع ضغط الدم، الفشل الكلوي الحاد، خلل في الكبد، تقلیل / تسطیح أو توقف التنفس، فقدان الوعي، االنوبات المرضیة، انھیار الدورة الدمویة في القلب، ردود فعل تحسسیة فوریة، بما في ذلك: والإغماء، وضیق في التنفس، وردود فعل الجلد.<br /><strong>إذا نسیت أن تتناول أقراص سیلیكتین</strong><br />إذا نسیت تناول جرعتك في الوقت المحدد، فاخذھا بمجرد أن تتذكر ما لم یكن الوقت قد حان تقریبا للجرعة التالیة. لا تأخذ جرعة مضاعفة لتعویض الجرعة المنسیة. فقط تأخذ الجرعة التالیة في الوقت المعتاد.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>ھذا الدواء یمكن أن یسبب آثار جانبیة، على الرغم من أنھا لا تصیب جمیع الأشخاص. توقف عن تناول سیلیكتین وراجع الطبیب أو إذھب إلى المستشفى على الفور إذا لاحظت الآثار الجانبیة التالیة:<br /><strong>شائع جداً: یؤثر على أكثر من 1 مستخدم من كل 10&nbsp;</strong>: أحداث الجھاز الھضمي السلبیة مثل عسر الھضم، والشعور المرضي والمرض، وآلام في البطن، والإمساك، وانتفاخ البطن، والبراز الرخو.<br /><strong>شائع: یؤثر على 1 إلى 10 مستخدمین من كل 100 :&nbsp;</strong>صداع.</p><p><strong>غیر شائع: یؤثر على 1 إلى 10 مستخدمین من كل 1000</strong>&nbsp;: الدوخة، والشعور بالدوخة أو الغزل، والنعاس، وفقر الدم، وزیادة في ضغط الدم، واحمرار واحتباس الماء والصودیوم، وزیادة مستویات البوتاسیوم. ھذا یمكن أن یؤدي إلى أعراض مثل: التغیرات في ضربات القلب، والخفقان، وضعف العضلات،التجشؤ، التھاب المعدة، نزیف الجھاز الھضمي، التھاب الفم، الحساسیة الفوریة، الحكة، الطفح الجلدي، تورم ناجم عن احتباس السوائل بما في ذلك تورم الكاحلین/الساقین، تورم الجلد أو الأغشیة المخاطیة المفاجئ مثل تورم حول العینین والوجھ والشفتین والفم أو الحلق، مما یجعل التنفس صعبا، والاضطراب اللحظي في فحوصات وظائف الكبد (مثل إنزیمات الكبد المرتفعة مثل ترانسامیناز أو زیادة الصباغ الصفراوي البیلیروبین)، یمكن للطبیب الكشف عن ھذه باستخدام اختبار الدم، واضطراب فحوصات التحقق من وظائف الكلى (مثل ارتفاع الكریاتینین أو الیوریا).<br /><strong>نادر: یؤثر على 1 إلى 10 مستخدمین من كل 10000&nbsp;</strong>: اضطرابات المزاج، والكوابیس، وتعداد الدم غیر طبیعي، بما في ذلك: (عدد الدم التفاضلي غیر طبیعي، وانخفاض عدد خلایا الدم البیضاء، وانخفاض عدد الصفائح الدمویة). ھذه الآثار الجانبیة قد تؤدي إلى زیادة خطر العدوى وأعراض مثل كدمات أو نزیف في الأنف. الرنین في الأذن، والشعور بنبضات قلبك، قرحة المعدة أو الجزء العلوي من الأمعاء الدقیقة، التھاب المريء، بدایة نوبات الربو، تقرح شدید في الجلد أو تقشیر، طفح جلدي، اضطرابات بصریة بما في ذلك: (عدم وضوح الرؤیة، التھاب الملتحمة)، التھاب الأمعاء الكبیرة. نادر جدا: یؤثر على أقل من مستخدم واحد من كل 10000 : ردود الفعل المتقشرة للجلد والتھاب احمراري للجلد متعدد الأشكال، والتھاب احمراري للجلد متعدد&nbsp;الأشكال ھو رد فعل تحسسي للجلد خطیر مما یسبب البقع، واللبان الأحمرأو مناطق أرجوانیة أو متقشرة، ویمكن أن تؤثر أیضا على الفم والعینین وغیرھا من سطوح الجسم الرطبة ، التھاب الكبد، وھذا یمكن أن یسبب أعراض مثل: (اصفرار الجلد أو مقل العیون، ألم في البطن، وفقدان الشھیة)، الفشل الحاد للكلى على وجه&nbsp; الخصوص في المرضى الذین یعانون من عوامل الخطر مثل أمراض القلب ، والسكري أو أمراض الكلى، ثقب في جدار الأمعاء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>یحفظ بعیداً عن متناول الأطفال وعن نظرھم.</li><li>یحفظ في درجة حرارة أقل من 30 م&deg;. یحفظ في العبوة الأصلیة.</li><li>لا تستخدم أقراص سیلیكتین بعد تاریخ انتھاء الصلاحیة المدون على الكرتون والشریط. یشیر تاریخ انتھاء الصلاحیة إلى آخر یوم من ذلك الشھر.</li><li>لا ینبغي التخلص من الأدویة عن طریق میاه الصرف الصحي أو النفایات المنزلیة. اسأل الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد بحاجة إلیھا. تساھم ھذه التدابیر في حمایة البیئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة ھي <strong>میلوكسیكام</strong>. المواد الأخرى ھي: كروسكارمیلوز صودیوم، لاكتوز، مایكروكریستالاین سیلیولوز، سیلیكا، صودیوم لوریل سلفات، مغنیسیوم ستیارات.<br />كل قرص 7.5 مغ یحتوي على: 7.65 مغ میلوكسیكام، وكل قرص 15 مغ یحتوي على: 15.30 مغ میلوكسیكام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">قرص سيليكتين 7.5 مغ هو أصفر فاتح دائري محدب محفور عليه &quot; SL1 &quot; على جانب واحد وخط فاصل على الجانب الاخر ، وقرص سيليكتين 15 مغ هو أصفر فاتح دائري مسطح مع حافة مائلة محفور عليه &quot; SL2&quot; على جانب واحد وخط فاصل على الجانب الاخر وكلاهما متوفر في عبوات سعتها 10 و 30 حبة.</p><p style="text-align:right">ليست جميع الاشكال مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة الحیاة للصناعات الدوائیة م.ع.م<br />ص.ب 1564 عمان 11118 الأردن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آذار من 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Selektine 7.5 mg tablets.
Selektine 15 mg tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of Selektine 7.5 mg contains 7.65 mg meloxicam (it contains 2% overage to account for loss during processing). 
Each tablet of Selektine 15 mg contains 15.30 mg meloxicam (it contains 2% overage to account for loss during processing). 
Excipient(s) with known effect: Each tablet of Selektine 7.5 mg contains 85.425 mg lactose monohydrate, so patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine. Each tablet of Selektine 15 mg contains 170.85 mg lactose monohydrate, so patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine. 
For the full excipients see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
Selektine 7.5 mg tablet: Light yellow round biconvex tablets, “SL1” engraved on one side and a break line on the other side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 
Selektine 15 mg tablet: Light yellow round biconvex tablets, “SL2” engraved on one side and a break line on the other side.
The tablet can be divided into equal doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Short-term symptomatic treatment of exacerbations of osteoarthrosis.<br />- Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral use<br />The total daily amount should be taken as a single dose, with water or another liquid, during a meal.<br />Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms . The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.<br />-&nbsp;<strong>Exacerbations of osteoarthrosis</strong>: 7.5 mg/day (one 7.5 mg tablet, half a 15 mg tablet). If necessary, in the absence of improvement, the dose may be increased to 15 mg/day (two 7.5 mg tablets).<br />-&nbsp;<strong>Rheumatoid arthritis, ankylosing spondylitis</strong>: 15 mg/day (two 7.5 mg tablets, one 15 mg tablet). According to the therapeutic response, the dose may be reduced to 7.5 mg/day (one 7.5 mg tablet, half a 15 mg tablet).<br /><strong>DO NOT EXCEED THE DOSE OF 15 MG/DAY.<br />Special populations</strong><br />Elderly patients and patients with increased risks for adverse reaction : The recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day. Patients with increased risks for adverse reactions should start treatment with 7.5 mg per day .<br /><strong>Renal impairment:</strong><br />In dialysis patients with severe renal failure, the dose should not exceed 7.5 mg per day. No dose reduction is required in patients with mild to moderate renal impairment (i.e. patients with a creatinine clearance of greater than 25 ml/min). (For patients with non-dialysed severe renal failure,&nbsp;<br /><strong>Hepatic impairment :</strong><br />No dose reduction is required in patients with mild to moderate hepatic impairment (For patients with severely impaired liver function,<br /><strong>Children and adolescents:</strong><br />Selektine tablets is contraindicated in children and adolescents aged under 16 years ( see section 4.3 ).</p><p>This medicinal product exists in other dosages, which may be more appropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This medicinal product is contra-indicated in the following situations:
 - Third trimester of pregnancy (see section 4.6 ‘Fertility, pregnancy and lactation’); children and adolescents aged under 16 years.
 - Hypersensitivity to meloxicam or to any of the excipients listed in section 6.1 or hypersensitivity to substances with a similar action, e.g. NSAIDs, aspirin. Meloxicam should not be given to patients who have developed signs of asthma, nasal polyps, angioneurotic edema or urticaria following the administration of aspirin or other NSAIDs.
 - history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy;
 - active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes ofproven ulceration or bleeding).
 - severely impaired liver function.
 - non-dialysed severe renal failure.
 - gastrointestinal bleeding, history of cerebrovascular bleeding or other bleeding disorders.
 - severe heart failure.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms .<br />The recommended maximum daily dose should not be exceeded in case of insufficient therapeutic effect, nor should an additional NSAID be added to the therapy because this may increase the toxicity while therapeutic advantage has not been proven. The use of meloxicam with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided. Meloxicam is not appropriate for the treatment of patients requiring relief from acute pain. In the absence of improvement after several days, the clinical benefit of the treatment should be reassessed.<br />- Any history of oesophagitis, gastritis and/or peptic ulcer must be sought in order to ensure their total cure before starting treatment with meloxicam. Attention should routinely be paid to the possible onset of a recurrence in patients treated with meloxicam and with a past history of this type.<br /><strong>Gastrointestinal effects</strong><br />GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events.<br />The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see section 4.5)&nbsp;.<br />Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.<br />In patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as heparin as curative treatment or given in geriatrics, anticoagulants such as warfarin, other nonsteroidal anti-inflammatory drugs, or acetylsalicylic acid given at doses =500 mg as single intake or = 3g as total daily amount the combination with meloxicam is not recommended.<br />When GI bleeding or ulceration occurs in patients receiving meloxicam the treatment should be withdrawn.<br />NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn&#39;s disease) as these conditions may be exacerbated.<br /><strong>Cardiovascular and cerebrovascular effects</strong><br />Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.<br />Clinical monitoring of blood pressure for patients at risk is recommended at baseline and especially during treatment initiation with meloxicam.<br />Clinical trial and epidemiological data suggest that use of some NSAIDs including meloxicam (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for meloxicam. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart<br />disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with meloxicam after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).<br /><strong>Skin reactions</strong><br />Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of Meloxicam. Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of<br />SJS or TEN is within the first weeks of treatment. If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, Meloxicam treatment should be discontinued. The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis. If the patient has developed SJS or TEN with the use of Meloxicam, Meloxicam must not be re-started in this patient at any time.<br /><strong>Parameters of liver and renal function</strong><br />As with most NSAIDs, occasional increases in serum transaminase levels, increases in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen and other laboratory disturbances, have been reported. The majority of these instances involved transitory and slight abnormalities. Should any such abnormality prove significant or persistent, the administration of Meloxicam should be stopped and appropriate investigations undertaken.<br /><strong>Functional renal failure</strong><br />NSAIDs, by inhibiting the vasodilating effect of renal prostaglandins, may induce a functional renal failure by reduction of glomerular filtration. This adverse event is dose-dependant. At the beginning of the treatment, or after dose increase, careful monitoring of diuresis and renal function is recommended in patients with the following risk factors:</p><ul><li>&nbsp;Elderly.</li><li>Concomitant treatments such as ACE inhibitors, angiotensin-II antagonists, sartans, diuretic.</li><li>Hypovolemia (whatever the cause).</li><li>Congestive heart failure.</li><li>Renal failure.</li><li>Nephrotic syndrome.</li><li>Lupus nephropathy.</li><li>Severe hepatic dysfunction (serum albumin &lt;25 g/l or Child-Pugh score =10)</li></ul><p>In rare instance NSAIDs may be the cause of interstitial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome.<br />The dose of meloxicam in patients with end-stage renal failure on haemodialysis should not be higher than 7.5 mg. No dose reduction is required in patients with mild or moderate renal impairment (i.e. in patients with a creatinine clearance of greater than 25 ml/min).<br /><strong>Sodium, potassium and water retention</strong><br />Induction of sodium, potassium and water retention and interference with the natriuretic effects ofdiuretics may occur with NSAIDs. Furthermore, a decrease of the antihypertensive effect of antihypertensive drugs can occur. Consequently, oedema, cardiac failure or hypertension may be precipitated or exacerbated in susceptible patients as a result. Clinical monitoring is therefore necessary for patients at risk.<br /><strong>Hyperkalaemia</strong><br />Hyperkalaemia can be favoured by diabetes or concomitant treatment known to increase kalaemia. Regular monitoring of potassium values should be performed in such cases.</p><p><strong>Combination with pemetrexed</strong><br />In patients with mild to moderate renal insufficiency receiving pemetrexed, meloxicam should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration.<br /><strong>Other warnings and precautions</strong><br />Adverse reactions are often less well tolerated in elderly, fragile or weakened individuals, who therefore require careful monitoring. As with other NSAIDs, particular caution is required in the elderly, in whom renal, hepatic and cardiac functions are frequently impaired. The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal. Meloxicam, as any other NSAID may mask symptoms of an underlying infectious disease.</p><p>&nbsp;The use of meloxicam may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of meloxicam should be considered.</p><p>Selektine tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.<br /><u>Risks related to hyperkalaemia:</u><br />Certain medicinal products or therapeutic groups may promote hyperkalaemia: potassium salts, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, non-steroidal anti-inflammatory drugs, (low-molecular-weight or unfractionated) heparins, cyclosporin, tacrolimus and trimethoprim.<br />The onset of hyperkalaemia may depend on whether there are associated factors.</p><p>This risk is increased when the above-mentioned medicinal products are co-administered with meloxicam.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Fertility</u><br />The use of meloxicam, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of meloxicam should be considered.<br /><u>Pregnancy</u><br />Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early<br />pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.<br />During the first and second trimester of pregnancy, meloxicam should not be given unless clearly necessary. If meloxicam is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as<br />possible.<br />During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose<br />- The foetus to:</p><ul><li>Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension).</li><li>Renal dysfunction, which may progress to renal failure with oligo-hydroamniosis.</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; The mother and the neonate, at the end of pregnancy, to:</p><ul><li>Possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.</li><li>Inhibition of uterine contractions resulting in delayed or prolonged labour.</li></ul><p>Consequently, meloxicam is contraindicated during the third trimester of pregnancy.</p><p><u>Lactation</u><br />While no specific experience exists for meloxicam, NSAIDs are known to pass into mother&#39;s milk. Administration therefore is not recommended in women who are breastfeeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>No specific studies on the effect on the ability to drive and use machineries have been performed. However, on the basis of the pharmacodynamic profile and reported adverse drug reactions, meloxicam is likely to have no or negligible influence on these abilities. However, when visual<br />disturbances including blurred vision, dizziness, drowsiness, vertigo or other central nervous system disturbances occur, it is advisable to refrain from driving and operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a) General Description</strong><br />Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).</p><p>Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.<br />The most commonly-observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur(see section 4.4). . Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn&#39;s disease(see section 4.4).have been reported following administration. Less frequently, gastritis has been observed.<br />Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported(see section 4.4).<br />The frequencies of adverse drug reactions given below are based on corresponding occurrences of reported adverse events in 27 clinical trials with a treatment duration of at least 14 days. The information is based on clinical trials involving 15197 patients who have been treated with daily oral doses of 7.5 or 15 mg meloxicam tablets or capsules over a period of up to one year.</p><p>Adverse drug reactions that have come to light as a result of reports received in relation to administration of the marketed product are included.<br />Adverse reactions have been ranked under headings of frequency using the following convention:<br />Very common (&gt;1/10); common (&gt;1/100 to &lt;1/10); uncommon (&gt;1/1,000 to &lt;1/100); rare (&gt;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000)<br /><strong>b) Table of adverse reactions</strong><br /><u>Blood and lymphatic system disorders</u><br />Uncommon: Anaemia.<br />Rare: Blood count abnormal (including differential white cell count), leukopenia, thrombocytopenia.<br />Very rare cases of agranulocytosis have been reported.<br /><u>Immune system disorders</u><br />Uncommon: Allergic reactions other than anaphylactic or anaphylactoid reactions<br /><u>Psychiatric disorders</u><br />Rare: Mood altered, nightmares<br /><u>Nervous system disorders</u><br />Common: Headache<br />Uncommon: Dizziness, somnolence<br /><u>Eye disorders</u><br />Rare: Visual disturbance including vision blurred; conjunctivitis<br /><u>Ear and labyrinth disorders</u><br />Uncommon: Vertigo<br />Rare: Tinnitus<br /><u>Cardiac disorders</u><br />Rare: Palpitations.<br />Cardiac failure has been reported in association with NSAID treatment.<br /><u>Vascular disorders</u><br />Uncommon: Blood pressure increased (see section 4.4), flushing.<br />Respiratory, thoracic and mediastinal disorders.<br />Rare: Asthma in individuals allergic to aspirin or other NSAIDs.<br /><u>Gastrointestinal disorders</u><br />Very common: Gastrointestinal disorders such as dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhoea<br />Uncommon: Occult or macroscopic gastrointestinal haemorrhage, stomatitis, gastritis, eructation<br />Rare: Colitis, gastroduodenal ulcer, oesophagitis<br />Very rare: Gastrointestinal perforation<br />Gastrointestinal haemorrhage, ulceration or perforation may sometimes be severe and potentially fatal, especially in elderly.<br /><u>Hepatobiliary disorders</u><br />Uncommon: Liver function disorder (e.g. raised transaminases or bilirubin)<br />Very rare: Hepatitis<br /><u>Skin and subcutaneous tissue disorders</u><br />Uncommon: Angioedema, pruritus, rash<br />Rare: Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria<br />Very rare: Dermatitis bullous, erythema multiforme<br /><u>Renal and urinary disorders</u><br />Uncommon: Sodium and water retention, hyperkalaemia, renal function test abnormal (increased serum creatinine<br />and/or serum urea)<br />Very rare: Acute renal failure in particular in patients with risk factors<br /><u>General disorders and administration site conditions</u><br />Uncommon: Oedema including oedema of the lower limbs.<br /><strong>c) Information Characterising Individual Serious and/or Frequently Occurring Adverse<br />Reactions</strong><br />Very rare cases of agranulocytosis have been reported in patients treated with meloxicam and other potentially myelotoxic drugs .<br /><strong>d) Adverse reactions which have not been observed yet in relation to the product, but which are generally accepted as being attributable to other compounds in the class</strong><br />Organic renal injury probably resulting in acute renal failure: very rare cases of interstitial nephritis, acute tubular necrosis, nephrotic syndrome, and papillary necrosis have been reported (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Severe poisoning may result in hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse and cardiac arrest. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs and may occur following an overdose.<br />Patients should be managed with symptomatic and supportive care following an NSAID overdose.<br />Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Non-Steroidal Anti-Inflammatory agent, Oxicams, ATC code: M01AC06<br />Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam family, with antiinflammatory, analgesic and antipyretic properties.<br />The anti-inflammatory activity of meloxicam has been proven in classical models of inflammation.<br />As with other NSAIDs, its precise mechanism of action remains unknown. However, there is at least one common mode of action shared by all NSAIDs (including Meloxicam): inhibition of the biosynthesis of prostaglandins, known inflammation mediators.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />Meloxicam is well absorbed from the gastrointestinal tract, which is reflected by a high absolute<br />bioavailability of about 90% following oral administration (capsule). Tablets, oral suspension and<br />capsules were shown to be bioequivalent.<br />Following single dose administration of meloxicam, median maximum plasma concentrations are<br />achieved within 2 hours for the suspension and within 5-6 hours with solid oral dosage forms<br />(capsules and tablets).<br />With multiple dosing, steady state conditions were reached within 3 to 5 days. Once daily dosing<br />leads to mean drug plasma concentrations with a relatively small peak-trough fluctuation in the<br />range of 0.4 - 1.0 &mu;g/mL for 7.5 mg doses and 0.8 - 2.0 &mu;g/mL for 15 mg doses, respectively (Cmin<br />and Cmax at steady state, correspondingly). Mean maximum plasma concentrations of meloxicam<br />at steady state are achieved within five to six hours for the tablet, capsule and the oral suspension,<br />respectively. Extent of absorption for meloxicam following oral administration is not altered by<br />concomitant food intake or the use of inorganic antacids.<br /><u>Distribution</u><br />Meloxicam is very strongly bound to plasma proteins, essentially albumin (99%). Meloxicam<br />penetrates into synovial fluid to give concentrations approximately half of those in plasma.<br />Volume of distribution is low, i.e. approx. 11 L after i.m. or i.v. administration, and shows<br />interindividual variation in the order of 7 - 20%. The volume of distribution following administration<br />of multiple oral doses of meloxicam (7.5 to 15 mg) is about 16 L with coefficients of variation<br />ranging from 11 to 32%.<br /><u>Biotransformation</u><br />Meloxicam undergoes extensive hepatic biotransformation. Four different metabolites of<br />meloxicam were identified in urine, which are all pharmacodynamically inactive. The major<br />metabolite, 5&#39;-carboxymeloxicam (60% of dose), is formed by oxidation of an intermediate<br />metabolite 5&#39;-hydroxymethylmeloxicam, which is also excreted to a lesser extent (9% of dose). In<br />vitro studies suggest that CYP 2C9 plays an important role in this metabolic pathway, with a minor<br />contribution from the CYP 3A4 isoenzyme. The patient&#39;s peroxidase activity is probably<br />responsible for the other two metabolites, which account for 16% and 4% of the administered dose<br />respectively.<br /><u>Elimination</u><br />Meloxicam is excreted predominantly in the form of metabolites and occurs to equal extents in<br />urine and faeces. Less than 5% of the daily dose is excreted unchanged in faeces, while only<br />traces of the parent compound are excreted in urine.<br />The mean elimination half-life varies between 13 and 25 hours after oral, i.m. and i.v.<br />administration. Total plasma clearance amounts about 7 &ndash; 12 mL/min following single doses orally,<br />intravenously or rectally administered.<br />Linearity/non-linearity<br />Meloxicam demonstrates linear pharmacokinetics in the therapeutic dose range of 7.5 mg 15 mg<br />following per oral or intramuscular administration.<br />Special populations<br />Patients with hepatic/renal insufficiency:<br />Neither hepatic, nor mild to moderate renal insufficiency has a substantial effect on meloxicam<br />pharmacokinetics. Subjects with moderate renal impairment had significant higher total drug<br />clearance. A reduced protein binding is observed in patients with terminal renal failure. In terminal<br />renal failure, the increase in the volume of distribution may result in higher free meloxicam<br />concentrations, and a daily dose of 7.5 mg must not be exceeded (see section 4.2).<br />Elderly:<br />Elderly male subjects exhibited similar mean pharmacokinetic parameters compared to those of<br />young male subjects.<br />Elderly female patients showed higher AUC-values and longer elimination half-lives compared to<br />those of young subjects of both genders. Mean plasma clearance at steady state in elderly<br />subjects was slightly lower than that reported for younger subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicological profile of meloxicam has been found in preclinical studies to be identical to that of NSAIDs: gastrointestinal ulcers and erosions, renal papillary necrosis at high doses during chronic administration in two animal species.<br />Oral reproductive studies in the rat have shown a decrease of ovulations and inhibition of implantations and embryotoxic effects (increase of resorptions) at maternotoxic dose levels at 1mg/kg and higher. Studies of toxicity on reproduction in rats and rabbits did not reveal teratogenicity up to oral doses of 4 mg/kg in rats and 80 mg/kg in rabbits.<br />The affected dose levels exceeded the clinical dose (7.5-15 mg) by a factor of 10 to 5-fold on a mg/kg dose basis (75 kg person). Fetotoxic effects at the end of gestation, shared by all prostaglandin synthesis inhibitors, have been described.<br />No evidence has been found of any mutagenic effect, either in vitro or in vivo. No carcinogenic risk has been found in the rat and mouse at doses far higher than those used clinically.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Croscarmellose sodium.</li><li>Lactose monohydrate.</li><li>Microcrystalline cellulose.</li><li>Colloidal anhydrous silica.</li><li>Sodium laurilsulfate.</li><li>Magnesium stearate.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package, in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/Aluminum blisters containing tablets.<br />Pack size for 7.5 mg tablets: 30 as commercially available.<br />Pack size for 15 mg tablets: 30 as commercially available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hayat Pharmaceutical Industries Co. PLC
P. O. Box 1564 Amman 11118 Jordan
Tel. +962 6 416 2607
Fax. 0096264163016
E-mail: hpi@nol.com.jo
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                23 February 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>